Biosynex Gestion

Gestion contrôle des critères 1/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Larry Abensur

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	9.4yrs
Propriété du PDG	6.2%
Durée moyenne d'occupation des postes de direction	pas de données
Durée moyenne du mandat des membres du conseil d'administration	9.4yrs

Mises à jour récentes de la gestion

Recent updates

PDG

Larry Abensur

9.4yrs

Titularisation

Mr. Larry Abensur has served as a Director at Biosynex S.A. since June 24, 2015 and serves as the Chief Executive Officer at Biosynex SA. He serves as the Chairman of Biosynex S.A. Mr. Abensur serves as th...

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Larry Abensur	Chairman & CEO	9.4yrs	pas de données	6.2% € 1.9m
Thierry Paper	Deputy CEO & Director	9.4yrs	€127.30k	0.99% € 299.7k
Thomas Lamy	Deputy CEO & Director	9.4yrs	pas de données	1.56% € 470.9k
Felix Agbalika	Member of Scientific Advisory Board	no data	pas de données	pas de données
Emmanuel Drouet	Member of Scientific Advisory Board	no data	pas de données	pas de données
Denis Gallot	Member of Scientific Advisory Board	no data	pas de données	pas de données
Vincent Sapin	Member of Scientific Advisory Board	no data	pas de données	pas de données
Marc Noizet	Member of Scientific Advisory Board	no data	pas de données	pas de données
Elie Fraenckel	Director	no data	pas de données	pas de données

9.4yrs

Durée moyenne de l'emploi

Conseil d'administration expérimenté: Les membres du conseil d'administration de 0DL sont considérés comme expérimentés (ancienneté moyenne 9.4 ans).

Biosynex Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

Biosynex SA, Annual General Meeting, Jun 07, 2024

No independent directors

No independent directors

Recent updates

New major risk - Share price stability

Biosynex SA, Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: €3.45 loss per share (vs €1.53 profit in FY 2022)

New minor risk - Shareholder dilution

First half 2023 earnings released: €1.94 loss per share (vs €2.99 profit in 1H 2022)

New minor risk - Market cap size

New major risk - Earnings quality

Biosynex SA (ENXTPA:ALBIO) acquired 57.33% interest in ProciseDx Inc. from Nestlé HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.

Biosynex SA (ENXTPA:ALBIO) signed an agreement to acquire 57.33% interest in ProciseDx Inc. from Nestlé HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.

Biosynex SA (ENXTPA:ALBIO) acquired Eye Care activity from LABORATOIRES INNOXA.

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 24%

Full year 2022 earnings released

Biosynex SA (ENXTPA:ALBIO) entered into a definitive merger agreement to acquire Chembio Diagnostics, Inc. (NasdaqCM:CEMI) for $17.2 million.

Investor sentiment improved over the past week

Biosynex SA (ENXTPA:ALBIO) acquired 75% stake in Medkoncept A/S.

Investor sentiment improved over the past week

No independent directors

First half 2022 earnings released

Biosynex SA (ENXTPA:ALBIO) acquired Doc2u SAS on October 12, 2022.

Biosynex SA (ENXTPA:ALBIO) alongside the two founders acquired Bhr Pharmaceuticals Limited.

Upcoming dividend of €2.00 per share

Full year 2021 earnings released: EPS: €10.08 (vs €3.52 in FY 2020)

No independent directors

Biosynex SA (ENXTPA:ALBIO) acquired PrimaDiag SAS.

Biosynex SA (ENXTPA:ALBIO) acquired Para'kito.

Full year 2021 earnings released

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Biosynex SA (ENXTPA:ALBIO) signed a binding letter of offer to acquire Human Health Business of Enalees.

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Biosynex SA (ENXTPA:ALBIO) commences an Equity Buyback Plan for 10% of its issued share capital, for €4.5 million, under the authorization approved on June 8, 2020.

Full year 2020 earnings released: EPS €3.43 (vs €0.12 in FY 2019)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Biosynex SA has completed a Follow-on Equity Offering in the amount of €15 million.

PDG

Titularisation

Membres du conseil d'administration

Durée moyenne de l'emploi